BBIO Stock - BridgeBio Pharma, Inc.
Unlock GoAI Insights for BBIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $221.90M | $9.30M | $77.65M | $69.72M | $8.25M |
| Gross Profit | $218.02M | $6.86M | $74.21M | $66.60M | $8.25M |
| Gross Margin | 98.3% | 73.7% | 95.6% | 95.5% | 100.0% |
| Operating Income | $-592,973,000 | $-607,370,000 | $-512,202,000 | $-576,632,000 | $-474,482,000 |
| Net Income | $-535,762,000 | $-643,202,000 | $-481,183,000 | $-562,539,000 | $-448,724,000 |
| Net Margin | -241.4% | -6913.9% | -619.7% | -806.9% | -5439.7% |
| EPS | $-2.88 | $-3.95 | $-3.35 | $-4.43 | $-4.10 |
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Visit WebsiteEarnings History & Surprises
BBIOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $-0.74 | — | — | — |
Q4 2025 | Oct 29, 2025 | $-0.88 | $-0.95 | -8.0% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.83 | $-0.95 | -14.5% | ✗ MISS |
Q2 2025 | Apr 29, 2025 | $-1.00 | $-0.88 | +12.0% | ✓ BEAT |
Q1 2025 | Feb 20, 2025 | $-1.09 | $-1.31 | -20.2% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-1.03 | $-0.86 | +16.5% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-1.09 | $-1.02 | +6.4% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.40 | $-0.05 | +87.5% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.95 | $-0.96 | -1.1% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.86 | $-1.08 | -25.6% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.86 | $-0.98 | -14.0% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.84 | $-0.92 | -9.5% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.86 | $-0.87 | -1.2% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-1.02 | $-0.93 | +8.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.92 | $-0.81 | +12.0% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-1.13 | $-1.19 | -5.3% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.83 | $-1.01 | -21.7% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.91 | $-1.06 | -16.5% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.93 | $-0.66 | +29.0% | ✓ BEAT |
Latest News
Frequently Asked Questions about BBIO
What is BBIO's current stock price?
What is the analyst price target for BBIO?
What sector is BridgeBio Pharma, Inc. in?
What is BBIO's market cap?
Does BBIO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BBIO for comparison